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SUMMARY. The total number, morbidity and mortality
attributed to viraemic hepatitis C virus (HCV) infections
change over time making it difficult to compare reported
estimates from different years. Models were developed for
15 countries to quantify and characterize the viraemic
population and forecast the changes in the infected pop-
ulation and the corresponding disease burden from
2014 to 2030. With the exception of Iceland, Iran, Lat-
via and Pakistan, the total number of viraemic HCV
infections is expected to decline from 2014 to 2030, but
the associated morbidity and mortality are expected to
increase in all countries except for Japan and South
Korea. In the latter two countries, mortality due to an
ageing population will drive down prevalence, morbidity
and mortality. On the other hand, both countries have
already experienced a rapid increase in HCV-related
mortality and morbidity. HCV-related morbidity and
mortality are projected to increase between 2014 and
2030 in all other countries as result of an ageing HCV-
infected population. Thus, although the total number of
HCV countries is expected to decline in most countries
studied, the associated disease burden is expected to
Abbreviations: G, genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IDU, injection drug use; Peg-IFN, pegylated interferon;
RBV, ribavirin; RNA, ribonucleic acid; SMR, standard mortality ratio; SVR, sustained viral response.
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increase. The current treatment paradigm is inadequate
if large reductions in HCV-related morbidity and mortal-
ity are to be achieved.
Keywords: diagnosis, disease burden, epidemiology, hepati-
tis C, hepatitis C virus, incidence, mortality, prevalence,
treatment.
INTRODUCTION
The global burden of hepatitis C virus (HCV) infections is
both substantial and increasing [1,2]. It was recently esti-
mated that global anti-HCV prevalence is 115 million indi-
viduals, 80 million of whom have active viraemic HCV
infections [3]. Studies have shown an increase in HCV
liver-related mortality [4], as well as cases of hepatocellular
carcinoma (HCC) and liver transplants attributable to HCV
[5–7]; however, robust epidemiological data on HCV and
HCV-related morbidity are not available in all countries.
To develop policies to address the growing HCV disease
burden, individual countries will require more accurate
morbidity and mortality data on a national level.
This study aimed to provide estimates for multiple coun-
tries of the current HCV disease burden and treatment
paradigm in 2014, including prevalence, incidence, diag-
nosis, treatment and mortality. A disease burden model
was then used to estimate the projected future disease bur-
den by the year 2030 in each country if the current trends
were to continue. This analysis is consistent with previ-
ously published work [8,9] to allow for comparison of
results across all of the countries assessed so far.
METHODOLOGY
Inputs
The historical epidemiology of HCV was gathered through
a literature search, analysis of unpublished data and dis-
cussion with expert panels [10]. When no input data were
available, analogues (data from countries with a similar
healthcare practice and/or risk factors) or expert inputs
were used. Ranges were used to capture uncertainty in
inputs with wider ranges implying greater uncertainty.
Model
A disease progression model was constructed in Microsoft
Excel (Microsoft Corp., Redmond, WA, USA) to quantify
the size of the HCV-infected population, by the liver disease
stages, from 1950 to 2030. Microsoft Excel was selected as
a platform due to its transparency, availability and mini-
mal need for operator training. The model was set up for
sensitivity and Monte Carlo analysis using Crystal Ball,
(Oracle Corp., Redwood City, CA, USA) an Excel add-in.
Beta-PERT distributions were used for all uncertain inputs.
The model has been previously described in detail [9]. It
started with the annual number of acute infections that
progressed to chronic HCV (viraemic) infection after
accounting for spontaneous clearance of the virus (Fig. 1).
The progression of these new cases was followed along
with all chronic infections from prior years. Unless speci-
fied, the scope of the model was limited to viraemic, HCV
ribonucleic acid (RNA)-positive cases. Nonviraemic cases
(those who spontaneously cleared the virus or were treated
and cured) were not considered even though they would
test positive to HCV antibodies and may still progress to
more advanced stages of liver disease despite viral clear-
ance [11]. The total number of cases, at each stage of the
disease, was tracked by age and gender.
The historical number of HCV infections and the age
and gender distributions were gathered through a litera-
ture search and discussions with an expert panel [10].
These data were used to estimate the historical number of
new HCV infections, as described below.
New hepatitis C virus infections and re-infection
When available, reported or calculated annual estimates of
new infections were used. In most countries, the number
of new HCV infections was not available and was therefore
back-calculated. At any point in time, the total number of
HCV infections equals the sum of all new infections minus
the number of spontaneously cleared, deceased and cured
cases.
The number of new infections was back-calculated using
a two-step process that first calculated the annual number
of new cases, followed by the age and gender distribution
of these cases. The annual number of new cases was calcu-
lated using the known number of total HCV infections in a
given year in a country. The model calculated the annual
number of all-cause mortality, liver-related deaths and
Fig. 1 The flow of the hepatitis C virus (HCV) disease
progression model.
© 2015 John Wiley & Sons Ltd
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cured cases, as described below. The Excel optimization
add-in, Solver, was used to determine an average number
of new infections per year. However, the annual number
of new cases did not remain flat since 1950. Thus, an
annual relative incidence value was used to describe the
change in the number of new infections over time. Relative
incidence was set to one in 1950, and a discussion with
the expert panel was used to identify the years when new
infections peaked using the risk factors common in the
country (nosocomial infections, injection drug use, etc.).
When immigration from endemic high-risk countries
was highlighted as an important source of new infections,
the annual number of new cases due to immigration was
calculated by gathering net annual immigration, by coun-
try of origin and from national databases regarding the
anti-HCV prevalence in the country of origin.
In the second step, the age and gender of the acute infec-
tions were calculated using the age and gender distribution
of the total infected population in a given year. The age and
gender distributions of the new infections in 1966 and every
5 years thereafter were modified to match the known distri-
bution of the prevalent population. The age and gender dis-
tributions in years 1950–1965 were set to equal 1966 and
trended linearly between the 5-year increments. Age and
gender allocation by year started in 1950 if when significant
risk factors were present prior to 1966 (e.g. Japan).
It was assumed that in the absence of better informa-
tion, future HCV infection and re-infection will remain the
same as they are today. This is a more conservative
approach than a dynamic model, which would show a
reduction in HCV incidence with treatment of high-risk
populations (treatment as prevention). This conservative
approach was deemed appropriate given the uncertainties
present for HCV epidemiology and lack of detailed data on
infection and re-infection rates.
Progression rates
Disease progression was simulated by multiplying the total
number of cases at a particular stage of the disease by a
progression rate to the next stage. The rates were gathered
from previous studies [1,12–19] or calculated using known
number of HCC cases/mortality, as explained previously
[9].
The number of new cases at a stage of the disease was
calculated by multiplying the progression rate and the total
number of cases at the previous stage of the disease in the
previous year. The total number of cases was adjusted for
ageing, all-cause mortality and cases cured in any given
year.
Transition probabilities to HCC and HCC-related death
were modified in Japan based on cancer registry data for
liver cancer incidence and 5-year survival rates [20].
Because the ratio of incident HCC to incident decompen-
sated cirrhosis is believed to be higher in Japan as com-
pared to other countries [21], transition probabilities to
decompensated cirrhosis were also adjusted. In addition,
the HCV epidemic began prior to 1950 in Japan [22], so
the model was modified to account for growth of the HCV-
infected population prior to 1950.
All-cause mortality
The all-cause mortality rates by age and gender were gath-
ered from the Human Mortality Database [23] unless sta-
ted otherwise. The rates were adjusted for incremental
increase in mortality due to injection drug use (IDU) and
transfusion, as described previously [24]. Unless specified, a
standard mortality ratio (SMR) of 10 (95% uncertainty
interval 9.5–29.9) was used for the portion of the HCV-in-
fected population who were active IDU between ages 15
and 44 [25–30]. An SMR of 2.1 (1.3–17.6) was applied to
all ages for the portion of the population infected due to
transfusion [31]. In all countries studied, new HCV infec-
tions due to transfusion were no longer a risk factor. A lin-
ear declining rate was applied to obtain the per cent of
total infections attributed to transfusion to zero by 2030.
The adjustments to all-cause mortality for active IDU and
transfusion were made using the following assumptions:
Estonia
The per cent of the HCV population infected through IDU
and transfusion was not available in Estonia, so data from
surrounding countries were used to inform expert consen-
sus. In 1995, it was estimated that 30% of the HCV popu-
lation was infected through transfusion, and in 2005, it
was estimated that 15% of the infected population were
IDU.
Hungary
In 2014, 7% of the viraemic population was infected via
IDU. The percentage was back-calculated using estimates
of 10 000 IDU in Hungary and an IDU HCV prevalence of
50% [32]. These estimates were based on previous needle
exchange data, expert opinions and recently published
data. In Hungary, experts estimate that 50% of the virae-
mic population was infected via transfusion in 2010.
Iceland
Based on data from the Centre for Health Security and Infec-
tious Disease Control during an early period of reporting, an
estimated 50% of infected cases reported IDU and an esti-
mated 4% of infected cases reported a history of transfusion,
but there are likely no new infections due to transfusion in
recent years. Based on expert consensus, approximately
85% of cases in Iceland have a history of IDU.
Indonesia
In 2012, 2.5% of the HCV-infected population was active
IDU. This percentage was back-calculated using estimates
© 2015 John Wiley & Sons Ltd
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of 70 000 IDU in Indonesia (N. Nugrahini 2015 personal
communication) and an IDU HCV prevalence of 40–80%,
based on data from a recent survey of viral diseases among
IDU (N. Nugrahini 2015 personal communication). Apply-
ing a spontaneous clearance rate of 20% suggests there
were between 22 400 and 43 680 viraemic infected IDU.
In 1994, a general population survey in Jakarta estimated
that 20% of the population was infected through transfu-
sion [33].
Iran
In 2007, it was estimated that 75% of the infected popula-
tion in Iran had been infected by IDU [34,35]. Based on
expert opinion, 4% of all HCV cases were infected via
transfusion procedures. The majority of new cases are due
to IDU, which is reflected in the young age distribution.
Japan
Based on an estimated 325 000 IDU in 2002 with anti-
HCV prevalence of 60% [36] and a viraemic rate of 70%
[37], there were 131 000 chronically infected IDU in
2002, equivalent to 6% of the viraemic population in this
year. In 1992, an estimated 35% of the HCV-infected pop-
ulation was infected through transfusion [38].
Latvia
In 2012/2013, approximately 11–18% of the HCV-infected
population was active IDU. This percentage was back-calcu-
lated using estimates of 8000–12 700 IDU in Latvia [39]
and an IDU anti-HCV prevalence of 75% [40]. In 2007,
approximately 8% of the HCV-infected population had
acquired their infection through blood transfusion [41].
Lebanon
In 2015, 9% of the HCV-infected population acquired their
infection through IDU. This percentage was back-calcu-
lated using a reported 30% anti-HCV prevalence among
IDU [42] and an estimate of 3000 IDU in Lebanon based
on expert input. In 2007, 15% of the HCV-infected popula-
tion had acquired their infection through blood transfusion
[43].
Lithuania
In 2014, approximately 9% of the HCV-infected population
was active IDU. This percentage was back-calculated using
estimates from the ASIS database of the Lithuania State
Mental Health Center. Of 5800 reported drug users in
Lithuania, 4190 (70%) were active IDU (expert consensus).
Furthermore, 2870 (70%) were reported to be HCV RNA-
positive [44]. Additional studies suggest an anti-HCV
prevalence of 90–95% [45,46] with a recent unpublished
estimate from Vilnius of 95% anti-HCV among IDU (Lia-
kina 2015 personal communication). In 1995, an esti-
mated 15% of the HCV-infected population had acquired
their infection through blood transfusion [47].
Pakistan
In 2005, it was estimated that 5% of the viraemic
population in Pakistan were active IDU and that 6% of
the viraemic population had been infected via transfu-
sion [36,40,48,49]. The vast majority of new HCV
infections in Pakistan are due to nosocomial transmis-
sion. There are additional risk factors in Pakistan
including sharing of smoking utensils, sharing of
toothbrushes, shaving by travelling barbers, unsteril-
ized piercing tools and unsterilized tattoo and acupunc-
ture procedures [50].
Romania
In 2005, there were approximately 101 000 IDU in Roma-
nia [36]. The anti-HCV prevalence among IDU in 2007
was 80% [51]. Applying that prevalence to the IDU popu-
lation from 2005 indicates approximately 83 000
HCV + IDU in 2012. Using a viraemic rate of 85%, as
determined by expert consensus, an estimated 12% of the
total infected population was IDU in 2012. In 2008, 10%
of the infected population had received their infection
through transfusion [52].
Saudi Arabia
The per cent of the infected HCV population that were IDU
was estimated at 9%. This rate was back-calculated using
an estimated anti-HCV prevalence among IDU of 14%
[53]. The per cent of HCV infections attributable to trans-
fusions was reported as 15% [54].
Slovenia
In 2007, a study of 75% of the diagnosed anti-HCV popu-
lation in Slovenia found that 34% acquired the infection
through IDU, 10% through transfusion before 1993 and
3% through haemodialysis [55]. Sexual contact (2%),
occupational exposure (1%), tattooing (0.5%), household
contact (0.3%) and mother to child transmission (0.1%)
accounted for the remaining known routes of transmission
[55].
South Korea
In 2009, an estimated 5% of the HCV-infected population
was active IDU, and 19% acquired HCV through transfu-
sion [56].
UAE
It is estimated that 4% of HCV-positive UAE nationals
are IDU. Expert consensus estimates a 20% HCV preva-
lence in IDU; this rate was combined with the rate of
0.5% IDU in the general population [57] to calculate
the number of IDU with HCV and then divided by the
total number of HCV-seropositive individuals. The pro-
portion of HCV cases that are due to previous blood
transfusion was estimated to be 40% according to
expert consensus.
© 2015 John Wiley & Sons Ltd
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Diagnosed
The total number of diagnosed cases was collected and
reported previously [10]. To estimate current and future
total diagnosed cases, it was assumed that the number of
newly diagnosed cases stayed the same as the last reported
year.
Treated and cured
As described previously [10], the total number of treated
patients with HCV was estimated. It was assumed that the
number of treated patients stayed constant after the last
reported year. It was also assumed that the number of
treated patients for each genotype was proportional to the
genotype distribution of the HCV-infected population [10].
The annual number of cured patients was estimated
using the average sustained viral response (SVR) rate in a
given year. A separate SVR was used for the major geno-
types, as shown in Table 1. Different methods were used to
estimate the average SVR. All countries took into consider-
ation a weighted average of different treatment options in
a given year – interferon based therapy in combination
with ribavirin (RBV) (dual therapy) or with RBV and a
protease inhibitor (triple therapy). Some also took into con-
sideration the percentage of the population who were
treatment-experienced and treatment-na€ıve on each treat-
ment option, while other countries took into account the
disease stages of the patients being treated (e.g. F1, F2, F3
and F4).
Treatment protocols
The pool of patients who could be treated was impacted by
explicit or implicit treatment protocols. Explicit protocols
were determined by national or international guidelines,
whereas implicit protocols were determined by actual prac-
tice in the country. In 2014, decompensated cirrhotic
patients were considered ineligible in all countries.
According to the literature, approximately 40–60% of
patients with HCV are eligible for Peg-IFN/RBV [58,59].
The definition of eligibility included contraindications to
the drugs (e.g. psychiatric conditions) as well as patient’s
preference. In this analysis, 60–95% of the patients were
considered treatment-eligible for standard of care (Table 1).
In each country, the expert panel provided the most
common stages of fibrosis considered for treatment
(Table 1). Many countries use, or are starting to use, non-
invasive testing methods to determine the level of fibrosis
on patients. However, the Metavir scale was used in this
model to represent the severity/stage of liver fibrosis. The
age of the patients was also considered. Table 1 outlines
the most common age bands considered for treatment. The
data presented here do not imply that patients with lower
Metavir score or older/younger patients were not treated
in each country. Instead, the data provided a range for the
majority of treated patients.
Future treatment protocols
In this analysis, it was assumed that the future treatment
paradigm will remain the same as today. Thus, all assump-
tions (the number of acute cases, treated patients, per cent
of patients eligible for treatment, treatment restrictions, the
number of newly diagnosed annually and the average SVR
by genotype) were kept constant in future years.
RESULTS
The results of the analysis for 2014 are shown in Table 1.
Figure 2 shows the age distribution of the HCV-infected
population by country. Table 2 compares the change in
HCV disease burden in 2014 and 2030, while Figs 3 & 4
show the projected HCV disease burden between the years
1950 and 2030. It should be noted that decompensated cir-
rhosis figures include those who received a liver transplant.
Estonia
Expert consensus and acute HCV diagnosis data, provided
by the Estonian Health Board, were used to estimate
annual incidence. Incidence was estimated to have peaked
in 2000 and was modelled to decrease relative to annual
reports of acute HCV diagnosis. In 2014, 200 new cases
were estimated.
It is estimated that there were 19 000 (13 000–
20 900) viraemic individuals in 2014. Viraemic infections
were estimated to have peaked at 20 900 in 2006. By
2030, viraemic infections were estimated to decrease to
13 700 (8300–15 400). In 2014, an estimated 6% of the
viraemic population experienced cirrhosis, HCC or liver
transplant. By 2030, this proportion was projected to
increase to 17%. The number of HCC and decompensated
cirrhosis cases was projected to increase through 2030,
when cases will number 60 and 200, respectively, more
than doubling the 2014 values.
Hungary
There are little data on the exact number of new infections
in Hungary. Experts agree that new infections peaked in
1993 due to blood transfusions. After 1993, there was a
rapid decrease in incidence, due to blood screenings. How-
ever, a rapid increase in new infections began in 2000 due
to a rise in IDU-related infections. Among IDU, new users
have very high infection rates. This is likely due to new
designer drugs that have very short half-lives, so they can
be injected several times per day, thus increasing transmis-
sion rates. There were an estimated 2200 new cases of
HCV infections in Hungary in 2014.
© 2015 John Wiley & Sons Ltd
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It is estimated that there were 52 200 (39 100–
65 200) viraemic individuals in 2014. Viraemic infections
were estimated to peak at 52 300 in 2017 before
decreasing to 50 800 cases in 2030. The number of HCC
cases was estimated to increase 45% from a base of 280
cases in 2014 to 420 cases in 2030. The number of
liver-related deaths in patients with chronic HCV was
forecasted to increase by 60% from a base of 290 in
2014 to 450 in 2030. Decompensated cirrhosis and cir-
rhosis cases were projected to increase by 60% and 45%
from a base of 390 and 4400, respectively, in 2014.
HCV is shown not only as increasing liver-related mortal-
ity, but may also increase liver-independent all-cause
mortality as well.
Iceland
Expert consensus was used to estimate annual incidence.
In 2014, it was estimated that there were 50 new cases in
Iceland.
It is estimated that there were 1100 (800–1200) virae-
mic individuals in 2014. Viraemic infections were esti-
mated to increase beyond the year 2030, when there will
be an estimated 1200 cases. In 2014, an estimated 6% of
the viraemic population experienced cirrhosis, HCC or liver
transplant eligibility. By 2030, this proportion was pro-
jected to increase to 12%. The number of HCC and decom-
pensated cirrhosis cases was projected to increase through
2030, when cases will number 4 and 10, respectively,
more than doubling the 2013 values.
Indonesia
Expert consensus was used to estimate annual incidence.
Prior to 1992, a survey in Jakarta showed the primary risk
of HCV transmission was through transfusion and
haemodialysis. From 1992 to 1994, the Indonesian Red
Cross stepped in to clean up the blood supply. During this
time, Indonesia was seen as a model for the international
community for clean blood. Although IDU was estimated
to increase in the late 1990s, the efforts to achieve a clean
blood supply and recent (2010) active harm reduction
measures were considered to support a decreasing inci-
dence. In 2014, it was estimated that there were 24 800
new cases.
It was estimated that there were 1 284 000 (447 000–
2 047 000) viraemic individuals in 2014. Total viraemic
infections were estimated to increase slightly to 1 303 000
by 2023 before returning to 1 288 000 by 2030. In
2014, an estimated 9% of the viraemic population experi-
enced cirrhosis, HCC or liver transplant eligibility. By
2030, this proportion was projected to increase to 15%.
The number of HCC and decompensated cirrhosis cases
was projected to increase through 2030, when cases will
number 5300 and 19 400, respectively, nearly doubling
the 2014 values.
Iran
Expert consensus combined with prevalence data was used
to estimate the number of new infections. A rapid increase
Fig. 2 Distribution of the 2014 hepatitis C virus (HCV)-infected population by age as a percentage of total number of
cases.
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in new infections, through IDU, occurred after the Iranian
revolution in 1979 and continued until 1998, when the
full impact of harm reduction programmes among injection
drug users and blood screening resulted in a sharp
decrease until 2005, upon which the incidence levelled
out. There were an estimated 8900 new viraemic HCV
cases in Iran in 2014.
In 2014, there were an estimated 186 000 (123 000–
250 000) viraemic individuals in Iran, increasing 14% to
213 000 individuals in 2030. The number of HCC cases
and liver-related deaths will increase by 195% and 215%,
from a base in 2014 of 110 and 140, respectively, by
2030. Compensated and decompensated cirrhosis cases will
increase 210% and 350% from a base of 3500 and 150,
respectively, in 2014.
Japan
Expert consensus was used to estimate annual incidence.
In 2014, it was estimated that there were 3300 new infec-
tions in Japan.
It was estimated that there are 1 014 000 (470 000–
1 173 000) viraemic individuals in 2014. Viraemic infec-
tions were estimated to have peaked at 2 992 000
(88 000–355 000) in 1988. In 2014, an estimated 55% of
the viraemic population experienced cirrhosis, HCC or liver
transplant eligibility. By 2030, this proportion was projected
to increase to 65%. The number of HCC and decompensated
cirrhosis cases was projected to decrease through 2030,
when prevalent cases will number 68 400 and 15 900,
respectively, as result of liver-related and all-cause mortality.
Latvia
Expert consensus was used to estimate annual incidence.
Incidence was estimated to have peaked in 2000 and
decreased only gradually since that time. The gradual
decrease was modelled due to continued transmission in the
IDU population as well as in general community and medical
settings where sterilization of tools is not mandated by law.
In 2014, it was estimated that there were 2000 new cases
occurring annually (100 per 100 000 persons) in Latvia.
Fig. 3 Change in viraemic hepatitis C virus (HCV) infections over time.
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It is estimated that there were 42 500 (27 400–
49 000) viraemic individuals in 2014. Viraemic infec-
tions were estimated to increase to 49 000 (30 500–
57 600) after 2030. The number of HCC cases was
projected to increase 90%, from 70 cases in 2014 to
130 cases in 2030. The number of decompensated cir-
rhosis cases and liver-related deaths was projected to
increase from 230 and 90 cases, respectively, in 2014
to 450 and 180 cases in 2030, a 95% increase for
each.
Fig. 4 Change in hepatitis C virus (HCV) disease burden over time.
© 2015 John Wiley & Sons Ltd
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Lebanon
It was estimated based on expert consensus that incidence
of HCV peaked in 1990. A sharp decline in new cases was
estimated through the 1990s before levelling out and
increasing slightly from 2000 to 2014. An estimated 280
new cases occurred in 2014.
In 2014, there were an estimated 7700 (3000–17 900)
viraemic individuals in Lebanon. Viraemic infections were
estimated to have peaked in 2006 at 8100 cases and were
Fig. 4 continued
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projected to decline slightly between 2014 and 2030 to
7400 (2430–18 800) cases. The number of HCC cases
attributable to HCV was projected to increase 25% by
2030 from a base of 30 cases. Compensated cirrhosis and
decompensated cirrhosis were also projected to increase
30% and 17%, respectively, from a base of 810 and 90
cases in 2014.
Lithuania
Expert consensus was used to estimate annual incidence.
Incidence was estimated to have peaked in 2000,
decreased until 2005 and remained stable after 2005. In
2014, 1000 new cases were estimated, an incidence of 35
per 100 000.
It is estimated that there were 33 500 (21 100–
40 300) viraemic individuals in 2014. Viraemic infections
were estimated to peak at 35 100 (22 000–43 000) in
2030. In 2014, an estimated 6% of the viraemic popula-
tion experienced cirrhosis, HCC or liver transplant eligibil-
ity. By 2030, this proportion was projected to increase to
13%. The number of HCC and decompensated cirrhosis
cases was projected to increase through 2030, when cases
will number 120 and 340, respectively, more than dou-
bling the 2014 values.
Pakistan
The results of a national survey study combined with expert
panel input were used to estimate the number of new infec-
tions [60]. Incidence peaked around 2005 and remained
constant from that point forward. There were an estimated
231 000 new viraemic HCV cases in Pakistan in 2014.
In 2014, there were an estimated 7 193 000
(5 069 000–8 126 000) viraemic individuals in Pakistan,
increasing to 7 529 000 individuals in 2030. The number
of HCC cases and liver-related deaths will increase by 30%
and 25% from a base in 2014 of 25 200 and 24 200,
respectively, by 2030. Similarly, cirrhotic cases and decom-
pensated cirrhosis cases will increase 30% and 25% from a
base of 501 000 and 78 900, respectively, in 2014.
Romania
According to expert consensus, in 2008, reported incidence
of HCV in Romania was nine per 100 000, with an esti-
mated 10% of cases reported. This corresponds to approxi-
mately 10 600 incident HCV cases in Romania in 2014.
HCV incidence was thought to have peaked before 2000.
It was estimated that there were 572 000 (420 000–
593 000) viraemic individuals in 2014. Viraemic infections
were estimated to have peaked at 611 000 cases in 2007
and were projected to continue to decline to 439 000
(328 000–461 000) cases in 2030. Liver-related mortality
was projected to increase by 30% by 2030, from 2700
deaths in 2014 to 3400 in 2030. Cases of HCC were pro-
jected to increase 25% to 2400 cases in 2030 from 1900
cases in 2014. Compensated cirrhosis and decompensated
cirrhosis were projected to increase by 25% and 30% from
a base of 62 900 and 6500 cases in 2014, respectively.
Saudi Arabia
It was estimated, based on expert consensus, that there
were approximately 2700 incident cases of HCV in 2010
(one case per 10 000 persons). The model showed inci-
dence increasing through the 1970s and 1980s and peak-
ing in the early 1990s at an estimated 4800 cases per
year. It was thought that the rise in incidence was due lar-
gely to the coinciding development of medical infrastruc-
ture and increase in the number of invasive procedures
and blood transfusions in Saudi Arabia before blood
screening was implemented. It was estimated that there
were 2200 new cases of HCV in 2014.
In 2014, the total number of viraemic cases of HCV was
estimated at 101 000 (75 400–181 000). Viraemic preva-
lence was estimated to increase slightly to 103 000
(75 900–186 000) by 2030, a 2% change. HCC preva-
lence was estimated at 160 cases in 2014 and was pro-
jected to increase to 470 by 2030, a 190% increase. Liver-
related mortality was expected to increase from 210 deaths
in 2014 to 670 deaths in 2030, a 225% increase. Decom-
pensated and compensated cirrhosis cases were projected
to increase by 510% and 185%, respectively, by 2030
from a base of 210 cases and 5400 cases in 2014.
Slovenia
According to expert consensus, incidence in Slovenia is
declining and was estimated at 140 cases in 2014. Expert
input also determined that the incidence peaked before
1993, when blood screening began. IDU currently presents
the biggest risk factor to the spread of HCV in Slovenia [61].
It was estimated that there were 6500 (4500–7300) vir-
aemic individuals in 2014. Viraemic prevalence was esti-
mated to peak in 2011 at 6700 cases. Assuming the
current treatment paradigm remains constant, there will
be an estimated 5100 (3100–5900) viraemic cases in
2030. An estimated 7% of the viraemic population experi-
enced compensated cirrhosis, decompensated cirrhosis,
HCC or liver transplant in 2014, and this proportion was
projected to increase to 15% by 2030. Cases of compen-
sated cirrhosis, decompensated cirrhosis and HCC were
projected to increase by 80%, 105% and 80%, respectively,
by 2030 under the current treatment paradigm.
South Korea
In 2014, it was estimated that there were 3900 new cases
and there were 242 000 (161 000–274 000) viraemic
© 2015 John Wiley & Sons Ltd
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individuals. Viraemic infections were estimated to have
peaked at 279 000 in 2004 and by 2030 were estimated
to be 146 000 (88 600–175 000). In 2014, an estimated
19% of the viraemic population experienced cirrhosis, HCC
or liver transplant eligibility. By 2030, this proportion was
projected to increase to 25%, despite an overall decreasing
number of advanced stage cases. The number of HCC and
decompensated cirrhosis cases was projected to decrease
18% and 12% to 1500 and 3800 cases, respectively, in
2030. The number of liver-related deaths (2200 in 2014)
will increase to 2300 annually in 2027, before decreasing
to 2000 in 2030.
UAE
It was estimated that there were 80 new cases of HCV
among UAE nationals in 2014. Incidence peaked at just
over 900 cases per year around 1991 before levelling
out to today’s incidence rate around 2005. It was
thought that the rise in incidence through the 1970s
and 1980s was largely due to increased iatrogenic infec-
tion relating to the increase in access to medical care
during that time. HCV blood screening began in the
early 1990s, leading to a sharp decline in incidence over
the next 10 years.
In 2014, the total number of viraemic cases was esti-
mated at 10 900 (7600–11 100). If the pre-2014 stan-
dard of care were continued, prevalence would be expected
to steadily decrease by 25% to 8100 (5500–8400) cases
by 2030. HCC prevalence would be expected to increase
from 30 to 40 cases between 2014 and 2030, a 35%
increase. Liver-related mortality was projected to increase
by 45% from an estimated 40 deaths in 2014 to 60 deaths
in 2030. Decompensated and compensated cirrhosis preva-
lences were estimated at 60 and 1000 cases, respectively,
in 2014 and were expected to increase by approximately
85% to 100 and by 35% to 1400 cases by 2030.
DISCUSSION
A modelling approach was used to forecast HCV morbidity
and mortality. As the HCV disease burden changes over
time, this approach allowed us to compare data across
countries reported in different years [10] by estimating the
disease burden in 2014 (Table 1).
As shown in Fig. 3, the total number of viraemic infec-
tions was expected to decline or remain flat in most coun-
tries in this analysis, with the exception of Iceland, Iran,
Latvia and Pakistan. The changes in the total number of
infections over time mainly reflect the past HCV incidence,
age-specific HCV prevalence and improvements in the safety
of blood products and standards of health care. The total
number of HCV infections reported here is likely lower than
other estimates, as this study focused on the number of vir-
aemic cases in the population. Those who spontaneously
cleared the virus or were treated and cured were not con-
sidered. The increase in the future total HCV infections is
caused by a higher number of annual new HCV infections
than mortality or cured. In Pakistan, the source of most
new infections is iatrogenic, while in Latvia, Iran and Ice-
land, the new infections are attributed to IDU. Japan and
South Korea both have relatively older HCV-infected popu-
lations (Fig. 2), and a rapid decline in total HCV infections
is projected as the result of an increase in mortality, as the
HCV-infected population ages. On the other hand, both
countries have already experienced a rapid increase in
HCV-related mortality and morbidity. In comparison, Iran
has a very young infected population and HCV-related mor-
bidity and mortality are expected to increase through
2030. This analysis focused on nationals in UAE and Saudi
Arabia. The inclusion of migrant workers, who are typically
younger, could result in a different age distribution and a
different estimate for total HCV infections.
Figure 4 shows the change in disease burden over time,
while Fig. 5 shows that the number of individuals with
late-stage liver disease was expected to continue to grow
past 2030 in most countries except for Japan and South
Korea. The decrease in the total number of individuals
with HCC and decompensated cirrhosis in these countries
(Fig. 5) is due to an increase in mortality as the population
ages. However, the percentage of the HCV-infected popula-
tion, still alive, with advanced liver disease will increase
43% in both countries between 2014 and 2030.
As shown in Table 1, viraemic HCV prevalence ranged
from 0.2% in Iran and Lebanon to 4% in Pakistan. The
countries with the highest diagnosis rates were Iceland
and Japan (85% and 75%, respectively), while Indonesia,
Romania, Lithuania and Pakistan were estimated to have
the lowest diagnosis rates (range: 10–17%). In addition, it
was estimated that 0.8–6% of the infected population is
newly diagnosed each year, with the lower end of the
range represented by Japan and the upper end of the range
represented by Iceland. However, it should be noted that
as Iceland has diagnosed approximately 85% of their
infected population, this high rate of newly diagnosed
patients is not expected to continue indefinitely.
The country with the highest treatment rate was Ice-
land, where 3% of the infected population is treated annu-
ally, followed by Estonia, Japan, Iran, Hungary Slovenia,
Lebanon, and Latvia with treatment rates ranging between
2% and 3%. Among the countries included in this analysis,
three had treatment rates <1% (0.01–0.7%): Indonesia,
Saudi Arabia and Romania.
Mortality (all-cause and liver-related) was driven by the
age of the infected population (Fig. 2) as well as risk fac-
tors such as IDU and transfusion (Table 1). Older popula-
tions had a higher all-cause mortality rate [23] and, in
addition, disease progression rates increased with age.
Thus, older individuals were more likely to have advanced
liver disease and liver-related deaths associated with HCV.
© 2015 John Wiley & Sons Ltd
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As stated in the Methodology section, active IDU cases also
had a higher mortality rate due to the high-risk behaviour
associated with drug use. Table 1 presents the percentage
of the infected population who were actively injecting
drugs. The all-cause mortality was adjusted accordingly for
this portion of the population.
In each country, details of the current treatment proto-
cols were gathered. For the purpose of the model, it was
Fig. 5 Change in the number of decompensated cirrhosis cases and hepatocellular carcinoma (HCC) cases over time.
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presumed that all treatment assumptions (including the
number of treated patients, treatment eligibility, the num-
ber of newly diagnosed cases, SVR and treated patient
segments) would remain constant between now and
2030. This was not meant to be a realistic scenario but
was rather a baseline that could be used to compare the
impact of new strategies to manage the future disease
burden [62]. Thus, this work does not imply that the cur-
rent treatment paradigm will remain as it is today.
Instead, the scenarios shown here represent what would
Fig. 5 continued
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be the outcome if the current paradigm were to continue
unchanged.
There are several limitations that may influence the out-
comes from this study. The distribution of new cases from
1950 to the most recent year of available data was back-
calculated using relative incidence and an estimation of
appropriate age and gender distribution. However, to esti-
mate the number of new infections after the year of known
prevalence, an analysis of the key risk factors was con-
ducted in each country. These risk factors included inci-
dence among IDU, nosocomial infection and the impact of
immigration. A key limitation of this study is the assump-
tion that the number of new cases will remain constant
after 2014. Therefore, an increase in incidence seen in
2014 could result in a higher total prevalence in 2030.
A second limitation is the assumption that diagnosis in
each country will be sufficiently high to provide a pool of
patients available for treatment. In reality, as the diagnosis
rate increases, it will become more difficult to find undiag-
nosed patients. Furthermore, even if diagnosed, not all
patients may have easy access to care. Thus, the ability of
a country to treat its HCV prevalent population may be
limited by the number of available diagnosed eligible
patients.
In addition, the model does not consider the potential
disease progression of cured patients with HCV. Previous
studies have indicated that it is possible for disease progres-
sion to continue in more advanced patients even after
achieving SVR, although this progression will occur at a
slower rate [11]. As the analysis presented in this study
was limited to HCV viraemic individuals, the data may
overestimate the reduction in cases of HCC and decompen-
sated cirrhosis.
In conclusion, this study illustrates that, in most coun-
tries, overall viraemic HCV prevalence is projected to
decrease due to a combination of an ageing prevalent pop-
ulation, treatment and a reduction in risk factors, mainly
the improvements in the safety of blood products and harm
reduction programmes for injection drug users. However,
morbidity and mortality attributable to HCV are expected
to increase as the current infected population progresses to
advanced stages of liver disease. In most countries included
in this analysis, the increased disease burden will likely not
be controlled without significant changes being made in
the overall treatment paradigm, including increases in
screening, diagnosis and treatment. This implies that coun-
tries will need to evaluate different strategies to help make
decisions on how to best manage the expected increase in
their HCV-related disease burden.
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